These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1905629)

  • 21. Insulin production following intravenous glucose, arginine, and valine: different pattern in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus.
    Fasching P; Ratheiser K; Nowotny P; Uurzemann S; Parzer S; Waldhäusl W
    Metabolism; 1994 Mar; 43(3):385-9. PubMed ID: 8139489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathophysiology of insulin secretion in diabetes mellitus.
    Ward WK; Beard JC; Halter JB; Porte D
    Adv Exp Med Biol; 1985; 189():137-58. PubMed ID: 3898762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus.
    O'Meara NM; Sturis J; Van Cauter E; Polonsky KS
    J Clin Invest; 1993 Jul; 92(1):262-71. PubMed ID: 8325993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
    Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
    Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of insulin sensitivity and secretion with the labelled intravenous glucose tolerance test: improved modelling analysis.
    Mari A
    Diabetologia; 1998 Sep; 41(9):1029-39. PubMed ID: 9754821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Normal hepatic insulin sensitivity in lean, mild noninsulin-dependent diabetic patients.
    Pigon J; Giacca A; Ostenson CG; Lam L; Vranic M; Efendic S
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3702-8. PubMed ID: 8855826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.
    Røder ME; Porte D; Schwartz RS; Kahn SE
    J Clin Endocrinol Metab; 1998 Feb; 83(2):604-8. PubMed ID: 9467581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of insulin secretion by insulin and glucose in type II diabetes mellitus.
    Garvey WT; Revers RR; Kolterman OG; Rubenstein AH; Olefsky JM
    J Clin Endocrinol Metab; 1985 Mar; 60(3):559-68. PubMed ID: 3882736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects.
    Groop L; Luzi L; Melander A; Groop PH; Ratheiser K; Simonson DC; DeFronzo RA
    Diabetes; 1987 Nov; 36(11):1320-8. PubMed ID: 3117609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Islet function and insulin sensitivity in the non-diabetic offspring of conjugal type 2 diabetic patients.
    Johnston C; Ward WK; Beard JC; McKnight B; Porte D
    Diabet Med; 1990 Feb; 7(2):119-25. PubMed ID: 2137751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects.
    Kawamori R; Bando K; Yamasaki Y; Kubota M; Watarai T; Iwama N; Shichiri M; Kamada T
    Diabetes Care; 1989; 12(10):680-5. PubMed ID: 2515048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin secretory capacity in Singapore diabetic subjects.
    Thai AC; Yeo PP; Chan L; Wang KW; Lui KF; Cheah JS; Tan BY
    Ann Acad Med Singap; 1985 Apr; 14(2):191-3. PubMed ID: 3898977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age-related alteration of pancreatic beta-cell function. Increased proinsulin and proinsulin-to-insulin molar ratio in elderly, but not in obese, subjects without glucose intolerance.
    Shimizu M; Kawazu S; Tomono S; Ohno T; Utsugi T; Kato N; Ishi C; Ito Y; Murata K
    Diabetes Care; 1996 Jan; 19(1):8-11. PubMed ID: 8720525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia.
    Della Casa L; del Rio G; Glaser B; Cerasi E
    Am J Med; 1991 Jun; 90(6A):37S-45S. PubMed ID: 1872303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diminished insulin secretory response to glucose but normal insulin and glucagon secretory responses to arginine in a family with maternally inherited diabetes and deafness caused by mitochondrial tRNA(LEU(UUR)) gene mutation.
    Brändle M; Lehmann R; Maly FE; Schmid C; Spinas GA
    Diabetes Care; 2001 Jul; 24(7):1253-8. PubMed ID: 11423511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diet treatment of newly presenting type 2 diabetes improves insulin secretory capacity, but has no effect on insulin sensitivity.
    Hosker JP; Kumar S; Gordon C; Bhatnagar D; France M; Boulton AJ
    Diabet Med; 1993 Jul; 10(6):509-13. PubMed ID: 8365085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals.
    Potter van Loon BJ; Radder JK; Frölich M; Krans HM; Zwinderman AH; Meinders AE
    Int J Obes Relat Metab Disord; 1992 Feb; 16(2):79-85. PubMed ID: 1316330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term gliclazide treatment improves the in vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin.
    Serradas P; Bailbé D; Portha B
    Diabetologia; 1989 Aug; 32(8):577-84. PubMed ID: 2528491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.